Date: Tuesday 25 October, 2022 & Wednesday 26 October, 2022
Location: Abuja, Nigeria
Hybrid Meeting: In-person & Online
The WHO R&D Blueprint Team and Coalition for Epidemic Preparedness Innovations (CEPI) together with the co-hosting partner organisations Nigeria Centre of Disease Control (NCDC) and Africa Centres for Disease Control and Prevention (ACDC), are organising a workshop on "Accelerating the licensure of Lassa vaccines Generating robust evidence on vaccine efficacy and safety".
The workshop will bring together Lassa fever disease experts, epidemiologists, clinical researchers, public health and regulatory authorities, vaccine developers as well as many other experts in the field.
The objectives of the workshop are:
- To discuss Lassa virus disease, epidemiology and immunology.
- To present current vaccine candidates under development.
- To outline the design options for clinical efficacy trials for Lassa vaccines.
- To develop a collaborative approach with key stakeholders to advance Lassa vaccine development and evaluation.
Presentations will be available
PRESENTATIONS
Session 1: Lassa fever disease, epidemiology, and immunology
Clinical Features of Lassa Fever in Nigeria
Clinical management of Lassa fever Disease
A Brief overview of Lassa fever epidemiology and current surveillance systems - LIBERIA
Overview of Lassa fever epidemiology and current surveillance systems in Guinea
Overview of Lassa fever epidemiology and current surveillance systems in Nigeria
Overview of Lassa Fever Epidemiology and Surveillance System in Sierra Leone
Preliminary data from ENABLE: A multi-country Lassa fever epidemiology study
Review of Lassa fever host immune response and protective immunityReview of Lassa fever host immune response and protective immunity
Session 2: Overview Lassa fever vaccine development programs
A global TPP: What do we want to achieve with a Lassa vaccine?
IAVI VSV Lassa Fever Vaccine Candidate Development Overview
CEPI-WHO LASSA Workshop INO-4500 and CELLECTRA™ 2000
EBS-LASV, a dual-attenuated rVSV-vectored vaccine candidate for Lassa fever
Potential regulatory pathways towards vaccine licensure
Session 3: Designing Phase 3 efficacy trials for Lassa fever vaccines
Considerations on case definitions and potential secondary / exploratory objectives & endpoints
Statistical considerations: Trial design and sample size
Some examples of statistical issues in the efficacy trial
Considerations for Vaccine Safety Assessment
Experiences in multi-country trials and platform trial approaches
Ebola Virus Disease in Liberia: Strategic Approach to EVD Vaccine Trials
Multinational cooperation for vaccine development
Session 4: Working group sessions
Proposed trial design and implementation and Regulatory and policy considerations
Collaborative approach to evaluate Lassa fever vaccines
Session 5: Ways forward and opportunities for collaboration
Community engagement and good participatory practices: lessons learned and existing tools
The role of a single DSMB and the outline of the governance framework for the trials
CEPI Equitable Access Provisions
Présentation de la fièvre de Lassa, Guinée
Session 6: Other enabling activities
Effectiveness of Ribavirin for Lassa Fever: Systematic Review
Towards use of standardized assays: the role of a central lab
Diagnostics: performance evaluation and access
Other Lassa fever research priorities relevant for vaccine evaluation
LIVE STREAM
